NuCana PLC
NCNA
Company Profile
Business description
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
Contact
3 Lochside Way
EdinburghEH12 9DT
GBRT: +44 1313571111
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
22
Stocks News & Analysis
stocks
Is this the $80 billion elephant Warren Buffett has been waiting for?
Morningstar’s Greg Warren says Berkshire may have little choice but to take a hard look at this huge potential acquisition.
stocks
Tesla: Board announces new pay package for CEO Elon Musk
A key provision of the new award is that Musk must remain in a senior leadership position at Tesla.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,019.70 | 97.70 | 1.10% |
| CAC 40 | 7,632.01 | 85.85 | 1.14% |
| DAX 40 | 23,757.69 | 331.72 | 1.42% |
| Dow JONES (US) | 44,173.64 | 585.06 | 1.34% |
| FTSE 100 | 9,128.30 | 59.72 | 0.66% |
| HKSE | 24,784.90 | 51.45 | 0.21% |
| NASDAQ | 21,053.58 | 403.45 | 1.95% |
| Nikkei 225 | 40,489.44 | 198.74 | 0.49% |
| NZX 50 Index | 12,781.89 | 97.85 | 0.77% |
| S&P 500 | 6,329.94 | 91.93 | 1.47% |
| S&P/ASX 200 | 8,759.40 | 95.70 | 1.10% |
| SSE Composite Index | 3,593.89 | 10.58 | 0.30% |